Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies

References

• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 2006;154:763–75
   PubMed Web of Science ®Google Scholar
• Choi KM, Yannakoulia M, Park MS, et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr 2011;93:19–26
   PubMed Web of Science ®Google Scholar
• Kim IK, Lee HJ, Kang JH, Song J. Relationship of serum retinol-binding protein 4 with weight status and lipid profile among Korean children and adults. Eur J Clin Nutr 2011;65:226–33
   PubMed Web of Science ®Google Scholar
• Mostafaie N, Sebesta C, Zehetmayer S, et al. Circulating retinol-binding protein 4 and metabolic syndrome in the elderly. Wiener Med Wochensch 2011;161:505--10
   Google Scholar
• Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, et al. Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem 2003;278:47636–43
   PubMed Web of Science ®Google Scholar
• Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 2009;58:1002–7
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Fucho R, Gorgun CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008;118:2640–50
   PubMed Web of Science ®Google Scholar
• Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005;16:543–8
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996;274:1377–9
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Tuncman G, Gorgun CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959–65
   PubMed Web of Science ®Google Scholar
• Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699–705
   PubMed Web of Science ®Google Scholar
• Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 2006;36:621–5
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405–13
   PubMed Web of Science ®Google Scholar
• Doi M, Miyoshi T, Hirohata S, et al. Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol 2011;10:44
   PubMed Web of Science ®Google Scholar
• Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006;103:6970–5
   PubMed Web of Science ®Google Scholar
• Hu WH, Qiao J, Li R, Wang LN. Relations of serum adipocyte fatty acid binding protein to sex hormone and lipoproteins in patients with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 2006;86:3186–9
   PubMedGoogle Scholar
• Mohlig M, Weickert MO, Ghadamgahi E, et al. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. Eur J Endocrinol 2008;158:517–23
   PubMed Web of Science ®Google Scholar
• Wang J, Tang J, Wang B, et al. FABP4: a novel candidate gene for polycystic ovary syndrome. Endocrine 2009;36:392–6
   PubMed Web of Science ®Google Scholar
• Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006;55:3536–49
   PubMed Web of Science ®Google Scholar
• Fiehn O, Wohlgemuth G, Scholz M, et al. Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J Cell Mol Biol 2008;53:691–704
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Kjotrod S, Vanky E, Romundstad P. Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2007;86:145–50
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Humpert PM. Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn 2008;8:289–99
   PubMed Web of Science ®Google Scholar
• Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev 2007;65:251–6
   PubMed Web of Science ®Google Scholar
• Karabouta Z, Barnett S, Shield JP, et al. Peripheral neuropathy is an early complication of type 2 diabetes in adolescence. Pediatr Diabetes 2008;9:110–4
   PubMed Web of Science ®Google Scholar
• Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552–63
   PubMed Web of Science ®Google Scholar
• Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metabol 2011;96:1827–34
   PubMed Web of Science ®Google Scholar
• Musarrat K, Kalathil D, Varughese GI. Metformin, B12 and homocysteine levels: the plausible cause or effect? J Formos Med Assoc 2008;107:505–6
   PubMed Web of Science ®Google Scholar
• Ulgen F, Herder C, Kuhn MC, et al. Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem 2010;116:57–62
   PubMedGoogle Scholar
• Esteban Jimenez O, Gonzalez Rubio F, Bunuel Granados JM, Navarro Peman C. Vitamin B12 deficiency secondary to metformin therapy. Med Clin (Barc) 2010;135:287–8
   PubMed Web of Science ®Google Scholar
• Yildizhan R, Ilhan GA, Yildizhan B, et al. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertil Steril 2011;96:246–50
   PubMed Web of Science ®Google Scholar
• Aigner E, Bachofner N, Klein K, et al. Retinol-binding protein 4 in polycystic ovary syndrome–association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab 2009;94:1229–35
   PubMed Web of Science ®Google Scholar
• Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. Br Med J 1971;2:685–7
   PubMed Web of Science ®Google Scholar
• Hutchison SK, Harrison C, Stepto N, et al. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care 2008;31:1427–32
   PubMed Web of Science ®Google Scholar
• Acezat Oliva J, Simo Cruzet E. Vitamin B12 deficiency in patients treated with metformin: an approach to adopt. Aten Primaria 2010;42:186–7
   PubMed Web of Science ®Google Scholar
• Rufenacht P, Mach-Pascual S, Iten A. Vitamin B12 deficiency: a challenging diagnosis and treatment. Rev Med Suisse 2008;4:2212–4, 2216–7
   PubMedGoogle Scholar
• Bino RJ, Hall RD, Fiehn O, et al. Potential of metabolomics as a functional genomics tool. Trends Plant Sci 2004;9:418–25
   PubMed Web of Science ®Google Scholar
• Azziz R. The Rotterdam 2003 criteria for defining PCOS: con (or how to define a syndrome). J Clin Endocrinol Metab 2006;91:781--5
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Stoica T, Verdonck L. The apparent free testosterone concentration, an index of androgenicity. J Clin Endocrinol Metab 1971;33:759–67
   PubMed Web of Science ®Google Scholar
• Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70
   PubMed Web of Science ®Google Scholar
• Hsu BG, Chen YC, Lee RP, et al. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 2010;74:327–31
   PubMed Web of Science ®Google Scholar
• Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009;23:3865–73
   PubMed Web of Science ®Google Scholar
• Mohlig M, Weickert MO, Ghadamgadai E, et al. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol 2007;157:195–200
   PubMed Web of Science ®Google Scholar
• Hidalgo SF, Prieto de Paula JM, Salado Valdivieso I. Metformin and vitamin B12 deficiency. Med Clin (Barc) 2010;135:286–7
   PubMed Web of Science ®Google Scholar
• Kauffman RP, Baker TE, Baker VM, et al. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American journal of obstetrics and gynecology 2008;198:670e1–7; discussion 670e7–10
   Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Expert Opin Ther Targets 2009;13:1205–26
   PubMed Web of Science ®Google Scholar
• Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg Clin North Am 2008;88:1175–94, vii
   PubMed Web of Science ®Google Scholar
• Wang SN, Yeh YT, Wang ST, et al. Decreased retinol binding protein 4 concentrations are associated with cholesterol gallstone disease. J Formos Med Assoc 2010;109:422–9
   PubMed Web of Science ®Google Scholar
• Carter D, Howlett HC, Wiernsperger NF, Bailey CJ. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab 2003;5:120–5
   PubMed Web of Science ®Google Scholar